Human herpesvirus 6 in transplant recipients: an update on diagnostic and treatment strategies.
Antiviral Agents
/ pharmacology
Disease Management
Disease Susceptibility
Hematopoietic Stem Cell Transplantation
/ adverse effects
Herpesvirus 6, Human
Humans
Molecular Diagnostic Techniques
Organ Transplantation
/ adverse effects
Premedication
Roseolovirus Infections
/ diagnosis
Transplant Recipients
Virus Activation
Journal
Current opinion in infectious diseases
ISSN: 1473-6527
Titre abrégé: Curr Opin Infect Dis
Pays: United States
ID NLM: 8809878
Informations de publication
Date de publication:
12 2019
12 2019
Historique:
pubmed:
1
10
2019
medline:
4
8
2020
entrez:
1
10
2019
Statut:
ppublish
Résumé
The current review article focuses on recent advances in the approach to the diagnosis and treatment of human herpesvirus 6B (HHV-6B) in hematopoietic cell and solid organ transplant recipients. Over the past few years, key studies have broadened our understanding of best practices for the prevention and treatment of HHV-6B encephalitis after transplantation. Moreover, important data have been reported that support a potential role of HHV-6B reactivation in the development of acute graft-versus-host disease and lower respiratory tract disease in transplant recipients. Finally, increasing recognition of inherited chromosomally integrated HHV-6 (iciHHV-6) and an expanding array of diagnostic tools have increased our understanding of the potential for complications related to viral reactivation originating from iciHHV-6 in donors or recipients. Recent advances in diagnostic tools, disease associations, and potential treatments for HHV-6B present abundant opportunities for improving our understanding and management of this complex virus in transplant recipients.
Identifiants
pubmed: 31567413
doi: 10.1097/QCO.0000000000000592
pmc: PMC7141773
mid: NIHMS1575637
doi:
Substances chimiques
Antiviral Agents
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
584-590Subventions
Organisme : NIAID NIH HHS
ID : K23 AI119133
Pays : United States
Références
J Infect. 2019 Jul;79(1):36-42
pubmed: 31075291
Biol Blood Marrow Transplant. 2012 Nov;18(11):1700-8
pubmed: 22641196
Transpl Infect Dis. 2012 Feb;14(1):33-9
pubmed: 21794043
Bone Marrow Transplant. 2011 Jun;46(6):863-9
pubmed: 20838386
Rev Med Virol. 2012 May;22(3):144-55
pubmed: 22052666
J Allergy Clin Immunol. 2017 Dec;140(6):1643-1650.e9
pubmed: 28392330
Am J Respir Crit Care Med. 2019 Jul 1;200(1):63-74
pubmed: 30742492
Clin Infect Dis. 2002 Feb 1;34(3):309-17
pubmed: 11774077
Biol Blood Marrow Transplant. 2018 Nov;24(11):2324-2336
pubmed: 29684567
Haematologica. 2019 Nov;104(11):2155-2163
pubmed: 31467131
J Clin Microbiol. 2016 May;54(5):1223-7
pubmed: 26888901
Blood. 2017 Aug 24;130(8):1062-1069
pubmed: 28596425
J Clin Microbiol. 2006 Apr;44(4):1571-4
pubmed: 16597897
Biol Blood Marrow Transplant. 2017 Oct;23(10):1759-1766
pubmed: 28668490
Am J Transplant. 2013 Feb;13 Suppl 3:67-77; quiz 77-8
pubmed: 23347215
Blood Adv. 2018 Jun 26;2(12):1367-1370
pubmed: 29898877
J Clin Virol. 2014 Feb;59(2):94-9
pubmed: 24380721
Blood. 2017 Apr 20;129(16):2316-2325
pubmed: 28209721
J Clin Microbiol. 2010 Jul;48(7):2536-40
pubmed: 20147642
Bone Marrow Transplant. 2019 Aug;54(8):1354-1360
pubmed: 30696997
Methods Mol Biol. 2018;1768:99-109
pubmed: 29717439
Biol Blood Marrow Transplant. 2018 Jun;24(6):1264-1273
pubmed: 29454651
Clin Infect Dis. 2013 Sep;57(5):671-81
pubmed: 23723198
Curr Opin Virol. 2014 Dec;9:53-60
pubmed: 25285614
Bone Marrow Transplant. 2017 Nov;52(11):1563-1570
pubmed: 28783148
Clin Infect Dis. 2018 Sep 14;67(7):1125-1128
pubmed: 29635334
J Clin Virol. 2014 Oct;61(2):289-92
pubmed: 25066883
Biol Blood Marrow Transplant. 2019 Feb;25(2):369-381
pubmed: 30292744
J Med Virol. 2016 Dec;88(12):2038-2043
pubmed: 27124385
Clin Chem. 2014 May;60(5):765-72
pubmed: 24594780
Clin Infect Dis. 2018 Jan 18;66(3):368-375
pubmed: 29020348
Bone Marrow Transplant. 2008 Feb;41(3):279-85
pubmed: 18037945
J Clin Oncol. 2017 Nov 1;35(31):3547-3557
pubmed: 28783452
N Engl J Med. 2005 Feb 24;352(8):768-76
pubmed: 15728809
Expert Rev Anti Infect Ther. 2014 Oct;12(10):1171-8
pubmed: 25120093
Biol Blood Marrow Transplant. 2009 Oct;15(10):1143-238
pubmed: 19747629
Blood. 2014 Aug 14;124(7):1198-9
pubmed: 25124787
Am J Transplant. 2018 Jun;18(6):1548-1551
pubmed: 29316259
Blood. 2015 Jun 11;125(24):3789-97
pubmed: 25918347
J Clin Virol. 2009 Sep;46(1):37-42
pubmed: 19505845
J Virol. 2019 Jan 17;93(3):
pubmed: 30429336
J Clin Oncol. 2019 Oct 10;37(29):2670-2681
pubmed: 31449472
Bone Marrow Transplant. 2013 Feb;48(2):257-64
pubmed: 22750998
Clin Transplant. 2019 Sep;33(9):e13518
pubmed: 30844089
NPJ Genom Med. 2018 Sep 5;3:25
pubmed: 30210807
Biol Blood Marrow Transplant. 2012 Nov;18(11):1638-48
pubmed: 22564265
Clin Infect Dis. 2014 Aug 15;59(4):545-8
pubmed: 24803376
Transpl Infect Dis. 2017 Feb;19(1):
pubmed: 27859994
Antiviral Res. 2019 Mar;163:50-58
pubmed: 30677427
Blood Adv. 2018 Feb 27;2(4):428-432
pubmed: 29487057
J Med Virol. 2012 Sep;84(9):1388-95
pubmed: 22825817
Biol Blood Marrow Transplant. 2018 Dec;24(12):2549-2557
pubmed: 30067953
Clin Infect Dis. 2019 Feb 1;68(4):632-640
pubmed: 29982441
N Engl J Med. 2017 Dec 21;377(25):2433-2444
pubmed: 29211658